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Abstract
The epidemiology of Clostridium difficile infection is changing as a
result of the epidemic spread of the hypervirulent North American
Pulsefield type 1 strain. Clinicians are likely to encounter this
disease more frequently than ever in their practice, and should be
familiar with the updates in its diagnosis and treatment.
In the present issue of Critical Care, Gould and McDonald
[1] provide a comprehensive, up-to-date review of Clostridium
difficile  – a pathogen of increasing concern worldwide.
Recognized as the main cause of antibiotic-associated
diarrhea for several decades [2], Clostridium difficile infec-
tion (CDI) had developed a reputation more as an economic
challenge than a therapeutic one. That perception has
changed dramatically in recent years, after several outbreaks
of unprecedented severity, with increased frequency of
complications such as septic shock, toxic megacolon,
colectomy, and death were reported in the United States and
Canada [3,4]. This different clinical picture is attributed to the
emergence of a new C. difficile strain, designated North
American Pulsefield type 1 (NAP1). This strain’s heightened
virulence correlates with 20-fold greater toxin production
compared with historical strains [1,2]. Intriguingly, the NAP1
strain has been found in cattle and other animals, as well as in
retail ground meat [5], but food-borne transmission has not
been proven.
In light of the changing epidemiology and spectrum of
C. difficile disease, what are the implications for clinicians?
Need for early diagnosis, with increased index
of suspicion in nontraditional populations
The majority of CDI still occurs in patients with well-
recognized risk factors – antibiotic exposure and advanced
age, hospitalization, or nursing-home residence. CDI has also
been reported, however, in patients previously considered at
low risk for the disease, such as healthy patients from the
community [6], postpartum women, and perhaps patients on
gastric acid suppressive medications [7]. The toxin enzyme
immunoassay remains the main diagnostic modality in most
clinical settings [6] but is rather insensitive, necessitating the
submission of at least two specimens to improve the
diagnostic yield. Prompt initiation of effective therapy can be
crucial, especially in light of the rapid progression to fulminant
disease observed with the NAP1 strain. Empiric treatment is
now recommended immediately after specimen collection for
patients with severe CDI [8,9], and the disease should be
suspected in patients with unexplained leukemoid reaction
even in the absence of diarrhea [10].
Changing treatment concepts
Metronidazole has been historically recommended as first-line
CDI therapy primarily due to its low cost, its noninferiority to
vancomycin, and its lower propensity for colonization with
vancomycin-resistant enterocci and staphylococci [8].
Metronidazole remains a viable option for mild to moderate
disease [1,9]. Recent data from observational studies and
clinical experience suggest that metronidazole’s efficacy may
be decreasing [11], and a switch to oral vancomycin is
indicated if at least some symptomatic improvement is not
observed after 1–2 days of metronidazole treatment [9]. Oral
vancomycin remains the preferred treatment for severe disease
– defined in a recent randomized controlled trial [12] as the
presence of pseudomembranous colitis or intensive care unit
hospitalization, or the presence of two or more of the following:
age >60 years, temperature >38.3°C, white blood cell count
>15,000 cells/mm,3 albumin <2.5 mg/dl. As emphasized by
Gould and McDonald in their review article [1], efforts must be
directed to ensure drug delivery to the lumen of the colon in
patients with decreased peristalsis and ileus [9].
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Early surgical consultation
Previously CDI was rarely a surgical disease, but recent
experience is demonstrating otherwise. Emergency colec-
tomy has been noted to improve survival in severely ill
patients [13]. The clinical challenge is in identifying the
patients warranting colectomy and its timing. In patients with
suspected severe CDI, and those with ileus or toxic
megacolon, an early surgical consultation should be obtained
[9,13].
Continuing challenges
Perhaps the most frustrating aspect of CDI for the patient
and physician is the high relapse rate (25%), and, in some
patients, the multiple recurrences after discontinuation of C.
difficile therapy [2]. This aspect of management is particularly
difficult since there are no formal treatment guidelines, and
the therapeutic options currently used – such as vancomycin
with long tapers or pulsed doses, fecal implants, use of
probiotics, or intravenous immunoglobulin – are based on
anecdotal evidence from case reports or case series [2,9].
A variety of new therapeutic agents are currently under
investigation, and they are nicely summarized in the article by
Gould and McDonald [1].The research into defining the role
played by the host’s immune responses in determining
disease outcome is particularly exciting [14], and immuno-
modulatory therapies with monoclonal antibodies and a C.
difficile vaccine are currently undergoing phase 2 clinical
trials [15].
Until better treatment options, with agents that remediate
disease more quickly and with fewer relapses, become
available, the responsibility for interrupting nosocomial C.
difficile transmission remains literally ‘in our hands,’ through
the proper use of hand hygiene, through consistent and early
isolation of infected patients, through antibiotic stewardship,
and thorough environmental cleaning.
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